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The  post-transcriptional  control  of gene  expression  mediated  by RNA-binding  proteins  (RBPs),  long  non-
coding  RNAs  (lncRNAs)  as well  as miRNAs  is  essential  to determine  tumor  cell  fate  and  thus  is  a major
determinant  in cancerogenesis.  The  IGF2  mRNA  binding  protein  family  (IGF2BPs)  comprises  three  RBPs.
Two members  of  the  family,  IGF2BP1  and IGF2BP3,  are  bona  ﬁde  oncofetal  proteins,  which  are  de  novo
synthesized  in  various  human  cancers.  In  vitro  studies  revealed  that IGF2BPs  serve  as  post-transcriptional
ﬁne-tuners  modulating  the expression  of  genes  implicated  in  the  control  of  tumor  cell  proliferation,  sur-
vival,  chemo-resistance  and  metastasis.  Consistently,  the  expression  of both  IGF2BP  family  members
was  reported  to  correlate  with  an  overall  poor  prognosis  and  metastasis  in  various  human  cancers.  Due
to the  fact  that  most  reports  used  a  pan-IGF2BP  antibody  for studying  IGF2BP  expression  in  cancer,
paralogue-speciﬁc  functions  can  barely  be  evaluated  at present.  Nonetheless,  the  accordance  of  IGF2BPs’
role  in promoting  an aggressive  phenotype  of  tumor-derived  cells  in vitro  and  their  upregulated  expres-
sion  in  aggressive  malignancies  provides  strong  evidence  that  IGF2BPs  are  powerful  post-transcriptional
oncogenes  enhancing  tumor  growth,  drug-resistance  and  metastasis.  This  suggests  IGF2BPs  as  powerful
biomarkers  and  candidate  targets  for  cancer  therapy.
©  2014  The  Authors.  Published  by Elsevier  Ltd.  This  is  an open  access  article  under  the  CC  BY-NC-SA. Introduction
The mammalian IGF2 mRNA-binding protein family (Gene
ymbol: IGF2BP) comprises three RNA-binding proteins with a con-
erved domain structure including two N-terminal RNA recognition
otifs (RRM) and four C-terminal hnRNP K homology (KH) domains
Fig. 1a; reviewed in: [1]). Diverse biological roles and distinct tar-
et mRNAs identiﬁed for the individual IGF2BP family members
ccount for the numerous synonyms and aliases assigned to protein
amily (CRD-BP, KOC, ZBP, VICKZ or Vg1RBP/Vera in Xenopus).
The ﬁrst family member described was IGF2BP1, which was  ini-
ially identiﬁed as a protein involved in the stabilization of the MYC
RNA [2]. The protein prevents MYC  mRNA degradation by bind-
ng to the coding region instability determinant (CRD) and thereby
∗ Corresponding author at: Division of Molecular Cell Biology, Institute
f  Molecular Medicine, Martin Luther University Halle-Wittenberg, Heinrich-
amerow-Strasse 1, 06120 Halle, Germany. Tel.: +49 345 5522860;
ax: +49 345 5522860.
E-mail address: stefan.huettelmaier@medizin.uni-halle.de (S. Hüttelmaier).
ttp://dx.doi.org/10.1016/j.semcancer.2014.07.006
044-579X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-sa/3.0/).
promotes tumor cell proliferation and survival in various cancer
contexts (reviewed in: [1]). Later on, IGF2BP1 was found to control
the subcellular sorting of the ACTB mRNA in primary ﬁbroblasts and
neurons by binding to the cis-acting zipcode in the ACTB mRNA’s
3′UTR [3]. By controlling the spatially restricted translation of the
ACTB mRNA, IGF2BP1 was proposed to enhance neurite outgrowth
and axonal guidance ([4]; reviewed in: [1]). The human IGF2BP2
was ﬁrst described in 1999 due to its association with the IGF2
mRNA [5]. Later on the protein, also termed p62, was  proposed
as an auto-antigen in hepatocellular carcinoma [6]. Most notably,
however, single nucleotide polymorphisms (SNPs) have been iden-
tiﬁed in the second intron of the human IGF2BP2 gene. These were
correlated with an elevated risk of type two diabetes by various
studies (reviewed in: [7]). Consistently, IGF2BP was  recently iden-
tiﬁed as a modulator of mTOR signaling and IGF2 mRNA translation
[8]. The human IGF2BP3, which of all human family members
shows the highest similarity to Xenopus Vg1/RBP, was initially
termed KOC and identiﬁed due to its high abundance in pancreatic
cancer tissue [9]. Since its ﬁrst identiﬁcation a bulk of literature
reported IGF2BP3 to be the mainly expressed family member in
human cancer (reviewed in: [10]). Despite their high degree of
der the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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Fig. 1. (a) Domain structure of IGF2BPs with two  N-terminal RNA recognition motifs (RRM1 and RRM2), the hnRNP K homology domains (KH1–KH4) and linker regions (L1,
L2).  S183 in L1 of IGF2BP3 is phosphorylated by the mTOR complex 2 and suggested to promote IGF2 mRNA translation [27]. MAPK-dependent phosphorylation of S402 in
L2  of Vg1/RBP, the Xenopus ortholog of IGF2BP3, was proposed to release Vg1 mRNA during meiotic maturation of Xenopus oocytes [26]. (b) IGF2BP3 enhances indicated
tumor  cell properties by promoting the expression of indicated target genes by either preventing mRNA decay or stimulating mRNA translation, as depicted in Table 1. (c)
The  speciﬁcity of IGF2BP3-directed antibodies was  analyzed by Western blotting of total protein isolated from non-transfected (1–3) or ES-2 cells transfected with GFP-
tagged  IGF2BP paralogues (4–6), respectively. Increasing amounts of total protein were analyzed in lanes 1–3. VCL (vinculin) served as a loading control. The expression of
GFP-tagged proteins was determined by a GFP-directed antibody supplied by Santa Cruz. Note that the DAKO-supplied antibody 69.1 (also termed L523) detects all IGF2BPs.
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fGF2BP3-selective antibodies were purchased from Santa Cruz (N-19) and MBL (R
ntibody  facility (BSBS) of the Technical University of Braunschweig, Germany.
imilarity the IGF2BP proteins exhibit quite different expression
atterns (reviewed in: [1]). Although highly abundant during
mbryogenesis [5], the only family member ubiquitously expressed
n adult mouse tissues is IGF2BP2 [1]. In cancer, however, de novo
ynthesis or a severe upregulation has been described mainly for
GF2BP1 and IGF2BP3 suggesting these two family members as bona
de oncofetal proteins ([5]; reviewed in: [1]).
All three IGF2BPs exhibit a high degree of identity (ranging
rom 66 to 74%) and even higher similarity (79–84%) at the amino
cid level. The sequence identity is most prominent in the RRM
nd KH domains suggesting the distinct biological functions of
GF2BPs to mainly be regulated via the highly variable linker regions
Fig. 1a). The C-terminal KH domains of the IGF2BPs are essential
or RNA-binding and thereby determine subcellular localization ofP). The mouse monoclonal antibody 6G8 was generated in collaboration with the
all three family members, which is typically characterized by a
mainly cytoplasmic, granular distribution [11]. Based on crystal
structures as well as NMR  studies of the C-terminal KH-3,4 di-
domain of IGF2BP1, also termed ZBP1, the current view suggests
an anti-parallel pseudo-dimer formation of the two KH domains
interacting with two appropriately spaced RNA motifs [12,13].
In vitro studies revealed that all four KH domains mediate RNA-
binding, whereas the RRM domains were proposed to promote
the stability of protein–RNA complexes and mediate the associa-
tion with other RBPs [11,14]. Despite the high degree of sequence
identity in the KH domains, all three paralogues associate with
the IGF2 mRNA but apparently exhibit distinct RNA-binding prop-
erties and presumably associate with variable target transcripts
([11]; reviewed in: [1]). However, all paralogues were described
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o control the turnover, translation and/or transport of their tar-
et mRNAs. Among all family members the most functional and
echanistic studies were performed on IGF2BP1 (reviewed in: [1]).
ittle is known about IGF2BP2, which essentially was  reported to
ontrol IGF2 mRNA translation, mTOR-signaling and the regula-
ion of PINCH and MURF expression (reviewed in: [1]). Although,
GF2BPs are mainly cytoplasmic [11,15–17], one report suggests
hat IGF2BP3 in concert with HNRNPM modulates the fate of cyclin
1, D3 and G1 encoding transcripts in the nucleus [18]. Although
he latter remains to be validated and might be due to aber-
ant nuclear protein staining of some commercial antibodies (data
ot shown), there is a common consensus that all IGF2BPs direct
RNA fate via cytoplasmic mRNPs. In these IGF2BPs were proposed
o associate with other RBPs, mainly or exclusively in a RNA-
ependent manner [11], to regulate the fate of “virgin” mRNAs,
hich have not undergone the pioneer round of translation and
hus remain associated with proteins of the exon-junction com-
lex (EJC) [19,20]. Presumably, IGF2BPs bind their target transcripts
lready at the site of transcription in the nucleus [21] and pro-
ect or “cage” their target mRNAs in cytoplasmic mRNPs (reviewed
n: [1]). The release of caged target mRNAs and thus their transla-
ion or decay is presumably modulated by cytoplasmic signaling
hich merges on IGF2BPs and potentially other RBPs associat-
ng in virgin mRNPs. Phosphorylation-dependent regulation of the
NA-binding activity of RBPs has been proposed as an essential
echanism modulating the cytoplasmic control of gene expres-
ion [22,23]. For IGF2BP1 as well as the Xenopus Vg1RBP (IGF2BP3)
hosphorylation by the SRC-kinase (IGF2BP1) or MAPKs (IGF2BP3)
n the linker region connecting the KH di-domains was reported to
odulate growth cone guidance [4,24,25] or the release of the Vg1
RNA from the vegetal cortex of Xenopus oocytes (Fig. 1a; [26]).
trikingly, mTOR-dependent phosphorylation in the linker region
onnecting the RRM and KH domains of IGF2BP1 and IGF2BP2 was
hown to enhance the translation of the IGF2 mRNA (Fig. 1a; [8,27]).
hosphorylation at a homologous residue was also reported for
GF2BP3; however, the functional relevance of this observation
emains yet to be evaluated [27].
. IGF2BP3’s role in modulating tumor cell fate
Although little is known about the role of IGF2BP3 in modu-
ating the cytoplasmic fate of mRNAs, IGF2BP3 like IGF2BP1 was
roposed to control the translation or turnover of various can-
idate target transcripts (Table 1). Notably, thousands of target
RNAs, yet a rather small and common binding motif, has been
escribed for all IGF2BPs based on PAR-CLIP [28]. These analy-
es yet remain to be validated but suggest a signiﬁcant overlap of
arget mRNA binding among IGF2BP paralogues. The most promi-
ent and frequently studied target mRNA of IGF2BPs obviously
s the IGF2 mRNA, or more precisely one IGF2 transcript vari-
nt comprising a highly structured 5′UTR, the leader 3 sequence.
hile initially reported to repress translation of the respective IGF2
ranscript [5], more recent evidence indicates that IGF2BPs pro-
ote IGF2 synthesis, presumably in a mTOR-controlled manner
8,27,29,30]. Although, the role of IGF2BP3 in the control of IGF2
RNA translation remains contradictory, recent studies indicate
hat an upregulation of the protein in human cancer might enhance
umor growth by promoting the expression of IGF2, as previously
uggested by in vitro studies [31]. Moreover, recent studies suggest
hat IGF2BP3 promotes tumor cell proliferation also by synergizing
ith HNRNPM in the nucleus leading to an enhanced expression of
yclins [18]. Recently, IGF2BP3 was shown to promote the expres-
ion of the architectural transcription factor HMGA2 by preventing
iRNA attack, predominantly via the let-7 family [16]. Consistently,
GF2BP3 was reported as an essential factor in tumor initiating cellscer Biology 29 (2014) 3–12 5
in hepatocellular carcinomas (HCCs), was  strongly correlated with
an enhancement of HMGA2 expression in HCCs and was identiﬁed
as one of the most severely upregulated RBPs in HCCs [15,32,33]. In
lung carcinoma cells, HMGA2 was proposed to enhance tumor cell
aggressiveness by acting as a competing endogenous RNA (ceRNA)
sequestering members of the let-7 miRNA family [34]. Thus, by
protecting and consequently enhancing the abundance of HMGA2
and potentially other let-7 targeting ceRNAs, IGF2BP3 like IGF2BP1
could enhance the expression of let-7 repressed oncogenes and
thereby promote tumor cell aggressiveness. In support of an onco-
genic role of IGF2BP3, the protein was  furthermore proposed to
stabilize the ABCG2 encoding mRNA [35]. This was suggested to
enhance the chemo-resistance of breast cancer-derived cells in
vitro.
In addition to growth, survival and chemo-resistance, IGF2BP3
was also reported to enhance the invasive potential of tumor cells
in vitro. This presumably involves the stabilization of the CD44,
CD164, MMP9  and PDPN encoding mRNAs (Fig. 1b; references
in Table 1). Moreover, these ﬁndings suggest that IGF2BP1 and
IGF2BP3 may  synergize in promoting tumor cell dissemination.
IGF2BP1 was shown to: (1) sustain mesenchymal-like tumor cell
properties by enhancing the expression of LEF [36]; (2) promote
tumor cell migration and pro-migratory adhesion by modulat-
ing actin dynamics in a HSP27-dependent manner [37,38]; (3)
enhance the formation of invadopodia by synergizing with IGF2BP3
in promoting the expression of CD44 [39]. In addition to in vitro
evidence, IGF2BP3 has also been correlated with an aggressive
and invasive cancer phenotype in some human malignancies. In
breast cancer-derived tumor cells the expression of IGF2BP3 was
enhanced by EGFR-signaling but suppressed by estrogen receptor
 (ER) signaling [40]. This was  well correlated with upregulated
expression of IGF2BP3 in highly aggressive triple-negative breast
carcinomas (TNBC; Table 2) and the IGF2BP3-dependent enhance-
ment of TNBC-derived tumor cell migration in vitro [40]. Moreover,
IGF2BP3 was reported to promote the chemo-resistance of breast
cancer-derived cells suggesting the protein to act as an oncogenic
factor in mammary carcinomas [35]. In osteosarcoma, IGF2BP3 was
proposed to be upregulated due to epigenetic modiﬁcations and
enhance anoikis resistance as well as the formation of syngeneic
subcutaneous Xenografts [17]. In oral squamous cell carcinoma
(OSCC), high IGF2BP3 expression was correlated with an overall
poor prognosis and a higher incidence of lymph node metasta-
sis (Table 2; [41,42]). This was  suggested to partially rely on the
IGF2BP3-dependent stabilization of the podoplanin (PDPN) mRNA
[43], since elevated PDPN expression was  proposed to enhance
tumor cell invasiveness and metastasis [44,45].
Consistent with various studies on IGF2BPs’ role in cancer, there
is strong evidence for a pro-metastatic role of IGF2BP1 in vivo, since
transgenic expression of the protein in mice induced primary breast
cancer lesions as well as metastasis [46]. In contrast, tumor for-
mation was  not observed by the transgenic expression of IGF2BP3
[47]. However, the only moderate phenotypic abnormalities in the
exocrine pancreas and parotid gland observed in the respective
mouse model might be explained by the moderate gastrointesti-
nal expression of the transgene. Thus, although in vivo evidence for
an oncogenic role of IGF2BP3 remains sparse, the protein clearly
promotes tumor cell proliferation, growth, drug-resistance and
invasiveness in vitro.
3. IGF2BP3’s expression in human cancerThe predominant IGF2BP paralogue described in the context
of human cancer is IGF2BP3 (reviewed in: [10]). This is largely
due to the fact that the vast majority of studies analyzing IGF2BP
expression in cancer rely on one antibody, supplied by DAKO,
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Table  1
Target mRNAs of IGF2BP3.
Target cis-Element Regulation Refs.
CD44 3′-utr Control of mRNA stability (mediated by I1 and 3) [39,81,131]
IGF2 5′-utr Translational control [30,131]
H19 ncRNA Unknown [30]
ACTB 3′-utr Unknown (in vitro binding) [11]
MYC  CRD Unknown (in vitro binding) [11]
CD164 Unknown Control of mRNA stability [40]
MMP9  Unknown Control of mRNA stability [40,131]
ABCG2 Unknown Unknown [35]
PDPN 3′-utr Control of mRNA stability [43]
HMGA2 3′-utr Protection from miR  directed degradation [16]
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hich is suitable for immuno-histochemical (IHC) analyses. How-
ver, although proposed to be IGF2BP3-speciﬁc, the DAKO-supplied
ntibody, is not paralogue-speciﬁc but recognizes all three IGF2BP
aralogues (Fig. 1c). In ovarian carcinoma-derived ES-2 cells, the
AKO-supplied antibody identiﬁed endogenous IGF2BP expression
ut also detected the expression of all other transiently expressed
FP-tagged IGF2BP paralogues. Notably, this observation is consis-
ent with a previous, independent report by Natkunam et al. [48].
nly few studies use paralogue-speciﬁc antibodies, for instance
he N-19 antibody supplied by Santa Cruz or the MBL-supplied
olyclonal serum directed against a C-terminal peptide of IGF2BP3.
hese antibodies are highly IGF2BP3-speciﬁc and show a negligi-
le cross-reactivity with the other paralogues in Western blotting
Fig. 1c). This is also observed for a monoclonal antibody (6G8)
aised by our lab in collaboration with the BSBS antibody facil-
ty (Fig. 1c). Hence, the expression of IGF2BPs in cancer has to be
onsidered with great caution in respect to paralogue-speciﬁcity.
owever, in view of the studies indicating an upregulated expres-
ion of IGF2BP1 and IGF2BP3 in various cancers on the basis of
T-PCR or paralogue-speciﬁc antibodies and the fact that these
oth paralogues are barely observed in the adult organism, we
ropose that upregulated expression determined by the DAKO-
upplied antibody strongly indicates expression of IGF2BP1 and/or
GF2BP3. Bearing in mind the above described limitation, we in the
ollowing summarize recent ﬁndings on the expression of IGF2BPs
n human cancer. Where available, we also indicated a correlation
f IGF2BP expression with prognosis and/or metastasis (Table 2).
.1. Breast cancer
In breast carcinomas, IGF2BP3 expression determined by the
AKO-supplied antibody was observed in the majority of invasive
riple-negative mammary carcinomas [49,50]. However, in basal-
ike breast cancer, a signiﬁcantly upregulated expression was  only
ound in adenoid cystic carcinomas [51,52].
.2. Gynecologic cancers
IGF2BP3 expression has been reported in all to date analyzed
ynecologic cancers including cervical cancer [53–55], endome-
rial cancer [56–61] and ovarian cancer [62,63]. Consistent with
ther cancers, IGF2BP3 expression was proposed to be increased
n high-grade malignancies, for instance 90% of endometrial clear
ell carcinomas [58] and where investigated was associated with
n overall poor prognosis, for instance in ovarian carcinomas [62].
owever, in the here reviewed studies the expression of IGF2BP3
as exclusively analyzed by the antibody supplied by DAKO.
hus, the paralogue-speciﬁc expression of the oncofetal IGF2BPs,
GF2BP1 or IGF2BP3, remains largely elusive. For ovarian cancer, our
wn analyses indicate that the expression of IGF2BP1, determinedy) translational control [18]
y) translational control [18]
y) translational control [18]
by a highly paralogue-selective polyclonal antibody, was correlated
with an overall poor prognosis [64]. In agreement, IGF2BP1 deple-
tion severely impaired the proliferation, survival and migratory
capacity of ovarian cancer-derived tumor cells in vitro suggesting
that both, IGF2BP1 and IGF2BP3, are important oncogenic factors
in ovarian cancer [38,64]. Notably, recent studies indicate that
IGF2BP2, termed VICKZ2 in the respective study, next to IGF2BP1 is
the most severely upregulated IGF2BP paralogue in serous ovarian
carcinoma and confers increased invasiveness of ovarian cancer-
derived tumor cells in vitro [65].
3.3. Gastrointestinal cancer
In the vast majority of studies addressing IGF2BP3 expression
in colorectal cancer, the DAKO-supplied antibody was  used. All
studies reported indicate a signiﬁcantly elevated expression of
IGF2BP3 in the vast majority of analyzed aggressive colorectal car-
cinomas (CRCs) compared to typically negative mucosa and suggest
IGF2BP3 expression to correlate with an unfavorable prognosis
[66–69]. Consistently, a strong correlation of IGF2BP3 expres-
sion was  observed with the pro-proliferative marker Ki67 [67]
and lymph node metastasis [69]. Likewise, in esophageal cancer
IGF2BP3 expression, analyzed by the pan-IGF2BP antibody supplied
by DAKO, was reported to correlate with an overall poor progno-
sis, higher tumor grading and was identiﬁed as a good predictor of
regional lymph node metastasis [70,71]. In gastric adenocarcino-
mas  (GAC), upregulated IGF2BP3 expression, determined again by
IHC-analyses using the DAKO-supplied antibody, was reported in
up to 87% of analyzed samples [72–74]. None or only faint staining
was observed in up to 10% of adjacent ‘normal’ mucosa. The lat-
ter could indicate moderate expression of IGF2BP2. As observed for
other gastrointestinal cancers, IGF2BP3 expression was correlated
with an unfavorable prognosis and metastasis in GAC  [72–74].
3.4. Liver cancer
IGF2BP3 expression was reported in carcinomas of the bile
duct [75–77], gallbladder carcinomas [78], intrahepatic cholangio-
carcinoma [79] as well as hepatocellular carcinomas [32,80,81].
As in other cancers, IGF2BP3 mainly determined by the DAKO-
supplied antibody, was correlated with an overall poor prognosis
and increased invasiveness [32]. Recent studies also provide func-
tional evidence for an oncogenic role of IGF2BP3 in HCCs. In
tumor initiating CD133+/CD49f+ stem cells (TICs) derived from HCC
mouse models as well as human patients, IGF2BP3 was  found to
be severely upregulated [15]. In vitro, IGF2BP3 was reported to
enhance chemoresistance and sustain pluripotency in HCC-derived
TICs. Consistently, in a study reporting upregulated expression of
IGF2BP3 in 68% of analyzed primary HCCs, the protein was pro-
posed to enhance the invasiveness and motility of HCC-derived
M. Lederer et al. / Seminars in Cancer Biology 29 (2014) 3–12 7
Table  2
IGF2BP expression in human cancer.
Cancer/organ Incidence (%) Correlation Refs.
Poor prognosis Metastasis/invasion
Breast
Mammary carcinoma 8–33 N/A N/A [10]
Basal-like breast cancer 21 N/A N/A [51]
Triple-negative breast carcinoma 33–56 + N/A [49,50]
Adenoid cystic breast carcinoma 81 N/A N/A [52]
Apocrine breast carcinoma 25 N/A N/A [52]
Gynecologic
Cervical carcinoma 50–100 N/A N/A [53–55]
Endometrial carcinomas 15–100 + N/A [56–61]
Ovarian cancer (clear cell; serous papillary) 95; 91 + N/A [62,63]
Gastrointestinal
Colorectal carcinoma 35–91 + + [66–69]
Esophageal adenocarcinoma 60–70 + + [70,71]
Gastric adenocarcinoma 74–87 + + [72–74]
Hepatic
Bile duct carcinomas 58–78 N/A N/A [75–77]
Gallbladder carcinoma 82 N/A N/A [78]
Intrahepatic cholangiocarcinoma 41 + N/A [79]
Hepatocellular carcinomas (TIC) 61–85 (100) + + [15,32,80,81]
Pancreatic
Pancreatic ductal adenocarcinoma 62–97 + + [82–86]
Genitourinary
Prostate cancer 18–83 + + [87–89]
Renal cell carcinoma 4–62 + + [90–93]
Testicular cancer and teratoma 63–100 N/A N/A [94,95]
Urothelial carcinoma 20–93 + + [96–100]
Lung and esophageal
Esophageal 38–97 N/A N/A [103,106]
Laryngeal squamous cell carcinoma 97 N/A N/A [103]
Lung 55–100 N/A N/A [101,102,104–106]
Non-small cell lung cancer 55 N/A N/A [104]
Large-cell neuroendocrine carcinoma 100 N/A N/A [101]
Small cell lung cancer 100 N/A N/A [101]
Head–Neck
Oral squamous cell carcinoma 56–100 + + [43,107–110,42,41]
Cutaneous cancer
Keratocanthomas 26 N/A N/A [111]
Squamous cell carcinoma 57 N/A N/A [111]
Melanoma 8–100 + + [112–115]
Merkel cell carcinoma 90 N/A N/A [116]
Thyroid cancer
Benign (FA, SNC, etc.) 0 N/A N/A [119]
Follicular thyroid carcinoma 69 N/A N/A [119]
Papillary thyroid carcinomas (PTC) 11 N/A N/A [119]
Follicular variant of PTC 38 N/A N/A [119]
Poorly differentiated 59 N/A N/A [117]
CNS
Sacral chordoma 63 N/A N/A [120]
Astrocytoma 31 + N/A [121]
Glioblastoma 88 N/A N/A [31]
Meningioma 7 N/A N/A [122]
Neuroblastoma 58 + N/A [123]
Lymphoid
Hodgkin (classical) lymphoma 94–100 N/A N/A [48,124–126]
Hodgkin (lymphocyte predominant) 92–100 N/A N/A [48,124–126]
Diffuse large B-cell lymphoma 78–85 N/A N/A [48,125]
Anaplastic large cell lymphoma 75–100 N/A N/A [48,125]
ALL/AML +/(100) N/A N/A [48,127]
Sarcoma
Leiomyoma 0 N/A N/A [129]
Leiomyosarcoma 52 + N/A [129]
Osteosarcoma 17–90 N/A N/A [17,128]
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ells in vitro by promoting the expression of the pro-stemness
actor HMGA2 [32]. These ﬁndings were supported by recent
tudies demonstrating that IGF2BP3 prevents miRNA-dependent
nhibition of HMGA2-expression [16]. Also in HCC, we  recently
emonstrated that IGF2BP1 and IGF2BP3 are among the ten most
pregulated RBPs, as revealed by microarray and RT-PCR analyses
33]. Like proposed for IGF2BP3, IGF2BP1 was found to act as an
ncogenic factor promoting the survival and proliferation of HCC-
erived cells in vitro and in vivo by enhancing the expression of MYC
nd Ki67 [33].
.5. Pancreatic cancer
In pancreatic cancer, IGF2BP3 expression was  exclusively
ssessed by IHC-analyses with three studies using the DAKO-
upplied antibody [82–86]. In agreement with other analyses,
GF2BP expression was determined in the vast majority of pan-
reatic ductal adenocarcinomas (PDAC) and was proposed for 97%
f invasive PDACs [83]. In contrast, the vast majority (>74%) of
nﬂamed pancreatic tissue was negative supporting the view that
GF2BPs, in particular IGF2BP1 and IGF2BP3, are potent biomarkers
f aggressive and invasive pancreatic carcinomas [83].
.6. Genitourinary cancer
In prostate cancer (PC), exclusively analyzed by the pan-
GF2BP antibody supplied by DAKO, the expression of IGF2BP3 was
bserved in 18–83% of analyzed samples [87–89] but considered
o be of low prognostic value [88]. However, a signiﬁcant upregu-
ation of IGF2BP expression was observed in only 15% of localized
ut strikingly 65% of palliatively treated metastatic PCs suppor-
ing the pro-invasive/-metastatic role of IGF2BP1/3 [87]. Notably,
pregulated IGF2BP3 expression was not correlated with elevated
GF2 mRNA or protein abundance. However, increased IGF2BP
erum levels were independently correlated with poor survival
n patients treated with radical prostatectomy [87,89]. In studies
ocusing on IGF2BP3 expression in renal cell carcinoma (RCC), all
sing the DAKO-supplied antibody, the expression of IGF2BPs was
orrelated with an overall poor prognosis and metastasis [90–93].
he vast majority (86%) of IGF2BP-positive patients developed
etastases whereas this was only observed for 14% of nega-
ive tumors [92]. In agreement, IGF2BP expression was reported
or about 50% of metastasizing RCCs but approximately only 4%
f non-disseminating RCCs [91]. Notably, IGF2BP expression was
lso observed in approximately 62% of analyzed metastases of
CC-origin [91]. In testicular cancer and male teratoma, IGF2BP3
xpression was observed in the vast majority of analyzed samples
94,95]. The study by Hammer et al. used a highly paralogue-
peciﬁc set of peptide-directed polyclonal antibodies targeting the
-terminus of IGF2BPs [94], similar to the MBL-supplied antibody
Fig. 1c). These tools revealed that IGF2BPs are expressed to differ-
nt extent in all cancer samples analyzed but only IGF2BP1 was
xpressed in all testicular cancers. In agreement, another study
sing the DAKO-supplied antibody revealed expression in a 100%
f analyzed metastatic testis teratoma [95]. Puzzling, however,
emains that none of the analyzed female mature teratomas was
ound to express IGF2BPs [95]. In urothelial carcinomas, IGF2BP3
xpression, again exclusively assessed by the DAKO-supplied anti-
ody, was correlated with an overall poor prognosis, increased
etastasis and was elevated with increased tumor grade/stage
96–100]. Notably, IGF2BP3 expression again was not associated
ith upregulated IGF2 or CD44 abundance, as also observed in
ther cancers [96].cer Biology 29 (2014) 3–12
3.7. Lung and esophageal cancer
Consistent with other carcinomas, upregulated expression of
IGF2BP3, once again exclusively analyzed by the DAKO-supplied
antibody, was observed in lung and esophageal cancer. Expression
was associated with higher tumor grading and reached a 100% in
small cell and metastatic lung cancer [101–106].
3.8. Head–neck cancer
A bulk of studies indicates IGF2BP expression to be upregu-
lated in oral squamous cell carcinoma (OSCC; [41–43,107–110]). All
studies relied on the DAKO-supplied antibody and thus paralogue-
speciﬁc expression signatures remain yet to be addressed.
However, as observed in other carcinomas, the expression of
IGF2BP3 was correlated with an overall poor prognosis [41,42,110]
and conﬁrmed as a predictor of lymph node status [108] and
metastasis [41,43,107]. In agreement, in vitro studies suggested
IGF2BP3-dependent enhancement of podoplanin (PDPN) expres-
sion, which was  proposed to promote tumor cell invasiveness [43].
Notably, PDPN and IGF2BP3 expression signiﬁcantly correlated
with lymph node metastasis in OSCC patients.
3.9. Cutaneous cancer
Various studies reported upregulated expression of IGF2BP3 in
keratoacanthomas, squamous cell carcinomas (SCC) of the skin
[111], melanoma [112–115] and merkel cell carcinoma [116]. All
these studies relied on the DAKO-supplied antibody and thus
paralogue-speciﬁc expression remains yet to be investigated. As
observed for various other solid cancers, higher incidence of
IGF2BP3 expression was  observed in invasive SCC of the skin [111]
and metastatic melanoma [113,114]. Notably, one study revealed
that the expression of IGF2BP1 (Chr.17q) and/or IGF2BP3 (Chr.7p) in
metastatic melanoma could be increased due to chromosomal gain
[115]. In agreement, we recently reported that IGF2BP1 enhances
the migratory potential and a mesenchymal-like cell phenotype in
melanoma-derived tumor cells [36].
3.10. Thyroid cancer
In thyroid cancers of follicular origin, IGF2BP expression, mainly
assessed by immunostaining using the DAKO-supplied antibody,
was proposed to be of diagnostic value [117–119]. IGF2BP3 expres-
sion was exclusively observed in malignant cancers and was
proposed to show high speciﬁcity in follicular thyroid carcinomas
and the follicular variant of papillary thyroid carcinomas [119].
In poorly differentiated variants of thyroid carcinomas, IGF2BP3
expression was  observed in 59% of cases [117].
3.11. CNS cancer
Mainly analyzed by the DAKO-supplied antibody, IGF2BP
expression was  reported in various CNS-derived cancers includ-
ing sacral chordoma [120], astrocytoma [121], meningioma [122],
glioblastoma [31] and neuroblastoma [123]. As observed in carci-
nomas, the expression of IGF2BPs was proposed to correlate with
an overall poor prognosis.
3.12. Lymphoid cancer
The expression of IGF2BPs has extensively been studied in lym-
phomas. IHC-based analyses revealed a high incidence of IGF2BP
expression, as determined by the DAKO-supplied antibody, with up
to a 100% of positive classical or lymphocyte-predominant Hodgkin
lymphomas [48,124–126]. RT-PCR based analyses in a small cohort
in Can
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f lymphomas suggested that IGF2BP3 is the predominant par-
logue expressed in primary lymphomas [48]. Strong expression
f IGF2BP3 was found in lymphocytes within the germinal center
GC), lymph nodes, the spleen and megakaryocytes, myeloid pre-
ursors as well as plasma cells of the bone marrow. Consistent with
his expression signature, IGF2BP3 expression was also observed in
en acute myeloid leukemia (AML) samples, as determined by stain-
ng of immature blasts [48]. One study also suggests that distinct
cute lymphoblastic leukemia (ALL) entities are characterized by
ltered IGF2BP expression, as revealed by RT-PCR analyses [127].
owever, the expression signatures of IGF2BPs in leukemia and
heir potential correlation with clinical parameters or diseases pro-
ression remain yet to be analyzed in detail.
.13. Sarcoma
In bone and soft tissue cancer, IGF2BP expression was reported
n osteosarcoma [17,128] and leiomyosarcoma [129]. One study
xplored the expression on the basis of the MBL-supplied anti-
ody (see Fig. 1c) which shows a high speciﬁcity for IGF2BP3 in
estern blotting suggesting that a vast majority (90%) of analyzed
steosarcomas expresses this paralogue [17]. Most notably, the
ame study also revealed that the depletion of IGF2BP3 impaired
he growth of syngeneic osteosarcoma Xenografts and the viabil-
ty as well as anoikis resistance of tumor cells in vitro. In 52%
f analyzed leiomyosarcomas but none of the 62 investigated
eiomyomas, IGF2BP3 expression was determined using the DAKO-
upplied antibody [129].
. Conclusions and perspectives
The bulk of correlative studies describing elevated expression or
e novo synthesis of IGF2BPs in human cancer and the various func-
ional in vitro studies provide strong evidence that IGF2BPs serve
ssential roles in modulating tumor cell fate and act in an onco-
enic manner in virtually every cancer analyzed to date. With this
eing said it remains largely elusive via which downstream effec-
ors the individual paralogues act, whether or not they synergize
n promoting tumor cell aggressiveness and which paralogue is the
ominant family member in which cancer.
In view of these and the above outlined limitations, we  pro-
ose that IGF2BP1 and IGF2BP3 are the main members in driving
umorigenesis, since there is comparatively little evidence for an
pregulated expression of IGF2BP2 in cancer or an oncogenic
ction of this paralogue in vitro (also reviewed in: [1]). IGF2BP1/3
ave been reported to promote tumor cell survival, proliferation,
nchorage-independent growth, chemo-resistance and tumor cell
nvasiveness in vitro. In agreement, an upregulated expression
f IGF2BPs has been correlated with an overall poor progno-
is and metastasis in various cancers (Table 2). The review of
ecent literature suggests that IGF2BP3 synergizes with HMGA2 in
nhancing tumor cell aggressiveness. By preventing miRNA attack,
GF2BP3 was proposed to promote the expression of HMGA2 [16].
otably, a similar mechanism was proposed for IGF2BP1, which
nhances BTRC1 expression by antagonizing miRNA-dependent
egradation of BTRC1 transcripts [130]. These ﬁndings support
he view, that both proteins serve essential roles in promoting
he expression of oncogenic factors by shielding these from being
egraded by tumor-suppressive miRNAs. In addition, IGF2BPs pro-
ote the expression of other oncogenic transcriptional regulators
ike MYC  and LEF1 [36,64], again two transcripts targeted by
umor-suppressive miRNAs. Thus it is tempting to speculate that
GF2BP1/3 enhance or sustain ‘oncogenic’ reprogramming of tran-
cription at the post-transcriptional level. Moreover, the target
ranscripts identiﬁed, for instance HMGA2, and the expressioncer Biology 29 (2014) 3–12 9
signatures of IGF2BP1/3, for instance in the hematopoietic system,
suggest that both factors sustain a stemness-like cell phenotype
(reviewed in: [1]). This is consistent with reports on a role of
IGF2BP1 in modulating stemness-like cell properties during devel-
opment and the strikingly upregulated expression of IGF2BPs in
aggressive and thus frequently de-differentiated cancers (reviewed
in: [1]). In addition to promoting a stemness-like tumor cell phe-
notype, IGF2BP1/3 were also shown to promote the migratory and
invasive potential of tumor cells in vitro. We  propose, that this is
mainly facilitated by IGF2BP1, which has been shown to modulate
actin dynamics, pro-migratory adhesion, tumor cell invasiveness
and was reported to induce metastasis in a transgenic mouse model
[36–39,46]. Evidence for a pro-invasive role of IGF2BP3 is mainly
based on loss-of-function studies yet downstream effectors remain
largely elusive or require further validation. Moreover, the only
to date reported mouse model does not support an oncogenic nor
pro-metastatic role of the protein [47].
In conclusion, we propose that IGF2BP1 and IGF2BP3 present
potent post-transcriptional oncogenes, which enhance tumor
cell aggressiveness. To further explore their potential as cancer
biomarkers it is essential to characterize their expression by the
use of paralogue-speciﬁc antibodies, which are available but largely
ignored by most studies. Moreover, additional transgenic mouse
models are required to test the role of both paralogues as well
as their putative synergistic action in vivo. These need to be ana-
lyzed with respect to the potential of both paralogues in inducing
cancer and promoting tumor cell dissemination. In view of promot-
ing our understanding of how IGF2BPs enhance a malignant tumor
cell phenotype, future studies should aim at a more holistic view
by comparing the role of all three paralogues side-by-side in the
cell models of choice. Finally, rescue studies are required to ﬁnally
prove via which downstream effectors IGF2BP paralogues facilitate
their multiple roles in promoting tumor cell aggressiveness.
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